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AMPK(AMP-activatedproteinkinase)signallingplaysakeyrole
in whole-body energy homoeostasis, although its precise role in
pancreatic β-cell function remains unclear. In the present stusy,
wethereforeinvestigatedwhetherAMPKplaysacriticalfunction
in β-cell glucose sensing and is required for the maintenance
of normal glucose homoeostasis. Mice lacking AMPKα2i nβ-
cells and a population of hypothalamic neurons (RIPCreα2KO
mice) and RIPCreα2KO mice lacking AMPKα1( α1KORIP-
Creα2KO) globally were assessed for whole-body glucose
homoeostasisandinsulinsecretion.Isolatedpancreaticisletsfrom
these mice were assessed for glucose-stimulated insulin secretion
and gene expression changes. Cultured β-cells were examined
electrophysiologically for their electrical responsiveness to
hypoglycaemia.RIPCreα2KOmiceexhibitedglucoseintolerance
andimpairedGSIS(glucose-stimulatedinsulinsecretion)andthis
was exacerbated in α1KORIPCreα2KO mice. Reduced glucose
concentrations failed to completely suppress insulin secretion
in islets from RIPCreα2KO and α1KORIPCreα2KO mice, and
conversely GSIS was impaired. β-Cells lacking AMPKα2o r
expressing a kinase-dead AMPKα2 failed to hyperpolarize in
responsetolowglucose,althoughKATP (ATP-sensitivepotassium)
channel function was intact. We could detect no alteration of
GLUT2 (glucose transporter 2), glucose uptake or glucokinase
that could explain this glucose insensitivity. UCP2 (uncoupling
protein 2) expression was reduced in RIPCreα2KO islets and the
UCP2 inhibitor genipin suppressed low-glucose-mediated wild-
type mouse β-cell hyperpolarization, mimicking the effect of
AMPKα2 loss. These results show that AMPKα2 activity is
necessary to maintain normal pancreatic β-cell glucose sensing,
possibly by maintaining high β-cell levels of UCP2.
Key words: AMP-activated protein kinase (AMPK), ATP-sens-
itive potassium channel (KATP), β-cell, glucokinase, pancreas,
uncoupling protein 2 (UCP2).
INTRODUCTION
Raised plasma glucose increases the amount of glucose taken
up by pancreatic β-cells predominantly through the glucose
transporter, GLUT2 [1]. This increase in glucose metabolism
occurs over the physiological range of glucose concentrations
by the action of the rate-limiting enzyme GK (glucokinase).
The raised β-cell metabolic ﬂux increases the ratio of cellular
[ATP]/[ADP], which closes KATP (ATP-sensitive potassium)
channels, leading to membrane depolarization, opening of
voltage-gated calcium channels, raised intracellular calcium and
insulin secretion [2]. Thus temporal ﬂuctuations of blood glucose
levels are directly linked to variations in insulin secretion by
the concerted activity of these key pancreatic β-cell proteins.
Therefore these proteins are essential for pancreatic β-cells
to mount an initial rapid insulin secretory response, which is
followed by a slower KATP-independent release of insulin. There
isstrongevidencethatdysfunctionalpancreaticβ-cellsarecentral
to the development of Type 2 diabetes [3,4]. A progressive
increase in basal insulin secretion (during fasting) along with
a much reduced or absent ﬁrst-phase of GSIS (glucose-stimulated
insulin secretion) are considered early and common defects in
Type 2 diabetes. Indeed, the loss or reduction of β-cell secretory
responsiveness to glucose, when imposed on a background of
peripheralinsulinresistance,islikelytoprecipitateearly-impaired
glucose tolerance leading rapidly to Type 2 diabetes.
Oral anti-diabetic drug treatment has evolved in recent years to
encompass the widespread use of metformin as a ﬁrst-line drug
for treatment of Type 2 diabetes [5]. Current evidence suggests
that metformin reduces blood glucose levels by decreasing liver
gluconeogenesis and increasing peripheral glucose uptake. The
mechanisms by which metformin performs these actions have
been linked to increased insulin action and the activation of
AMPK (AMP-activated protein kinase). Consequently, AMPK
has attracted considerable attention as a potential target for the
treatment of Type 2 diabetes [6].
AMPK acts as a cellular integration node for various nutrient
and hormone signals, and subsequent changes in AMPK activity
regulates multiple metabolic pathways of glucose metabolism
[7]. Thus there may be an expectation for AMPK to be
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critically involved in the regulation of insulin secretion by
glucose. Indeed, diminished AMPK activity has been reported
in islets from Type 2 diabetic patients [8]. However, the
precise role of AMPK in the regulation of insulin secretion
from β-cells is presently unclear and controversial. Activation
of AMPK by AICAR (5-aminoimidazole-4-carboxamide-1-β-D-
ribofuranoside), metformin or overexpression of a constitutively
active form of AMPK reduces GSIS in rodent and human islets
[9–12]. In contrast, overexpression of a dominant-negative form
of AMPK is reported to increase insulin release at low glucose
concentrations[10].However,othershavefailedtoreplicatethese
ﬁndings [13,14], generating uncertainty over the role of AMPK
in insulin secretion. Therefore to deﬁne the role of AMPK in β-
cell function, we generated mice deﬁcient in AMPKα2 (with or
without global deletion of AMPKα1) in β-cells and examined the
relationshipbetweenAMPKactivityandthemechanismsthought
to mediate normal glucose sensing.
MATERIALS AND METHODS
Animals
Floxed AMPKα2 allele RIPCre mice (The Jackson Laboratory)
were crossed to generate compound heterozygote mice. Double-
heterozygote mice were crossed with AMPKα2
+/ﬂ mice to
obtain WT (wild-type), ﬂox
+/+, Cre and Creﬂox
+/+.M i c e
lacking AMPKα2i nRIPCre-expressing cells were designated
RIPCreα2KO mice. RIPCreα2KO and AMPKα1KO mice were
crossed to generate mice lacking AMPKα1 globally (α1KO)
and AMPKα2 in RIPCre-expressing cells (α1KORIPCreα2KO
mice). All mice were maintained on a 12-h light/12-h dark cycle
with free access to water and standard mouse chow (4% fat,
RM1; Special Diet Services) and housed in pathogen-free barrier
facilities. All procedures were in accordance with the UK Home
Ofﬁce Animal Procedures Act of 1986 and approved by the
University of Dundee and University College London Animal
Ethics Committees. All mice were studied with appropriate
littermate controls. Genotyping of mice was performed by PCR
ampliﬁcation of tail DNA as described previously [15,16].
Physiological measurements
Body weight and feeding measurements, and tolerance tests were
performed as described previously [15,17]. Blood glucose and
plasma insulin levels were determined using mouse ELISAs
(Linco Research).
Gene expression studies
Quantitative PCR was performed as described previously
[15,16]. Expression levels of AMPKα2, Gck (glucokinase
gene), HMOX1 (haem oxygenase 1), GPX4 (glutathione
peroxidase 4), NPY (neuropeptide Y), Nrf1 (nuclear respiratory
factor 1), Pgc1α (peroxisome proliferator-activated receptor γ
coactivator 1-α), POMC (pro-opiomelanocortin), Slc2a2 [solute
carrier family 2 (facilitated glucose transporter) member 2;
previously known as Glut2], SOD2 (superoxide dismutase 2),
SUR1 (sulfonylurea receptor 1), Tfam (transcription factor A,
mitochondrial)andUCP2(uncouplingprotein2)werenormalized
to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) or
HPRT (hypoxanthinephosphoribosyltransferase1)anddatawere
analysed using the 2
− Ct method [15].
Figure 1 Reduction in islet and hypothalamic AMPKα2i nRIPCreα2KO
mice
(A)DetectionofthedeletionoftheAMPKα2 alleleinRIPCreα2KO mice.DNAwasextractedfrom
different tissues (T,tail; L, liver; M, skeletal muscle;F,fat; C,cerebralcortex; Hy, hypothalamus;
I, islets of Langerhans) and recombination of the ﬂoxed AMPKα2 allele was detected by PCR.
The presence of the 750bp band indicates deletion of AMPKα2. Recombination was only
detectedinisletsofLangerhansandthehypothalamusfromRIPCreα2KO mice.APCRwithIL2
(interleukin-2) as an internal control shows the presence of DNA template in all of the samples.
La, DNA ladder. (B) Representative immunoblot for AMPKα2 from control and RIPCre2αKO
islets.
Western blot analysis
Islet and hypothalamic lysates were prepared as described
previously [15–17] and immunoblots probed with polyclonal
antibodiesagainstATPsynthase(Abcam),AMPKa2(suppliedby
DavidCarling)andβ-actin(CellSignalling),withECL(enhanced
chemiluminescence; Amersham Biosciences) detection.
Pancreas morphometry
Antibodies used were mouse anti-insulin (I-2018; Sigma–
Aldrich), rabbit anti-glucagon (ab9379; Abcam), chicken anti-
mouse Alexa Fluor® 594 and chicken anti-rabbit Alexa Fluor®
488 (both Molecular Probes/Invitrogen). Confocal images were
captured using a Carl Zeiss LSM 700 laser scanning microscope
with 20× air objective.
Islets and CRI-G1 (Cambridge rat insulinoma-G1) experiments
Mousepancreaticisletisolation,isletinsulinsecretionstudiesand
β-cell culture were performed as described previously [16,18].
Treatments of CRI-G1 cells with Compound C (Calbiochem),
AICAR (Toronto Research Chemicals) and A-769662 were
carried out in normal saline+ −10 mM glucose. Hexokinase
activity in CRI-G1 cells was measured as described previously
[19]. Cell lysates were prepared for immunoblotting and analysis
as described previously [20]. For glucose uptake, the ﬂuorescent
glucose analogue 2-NBDG (Molecular Probes) was applied at
100 μMinthepresenceofglucose+ −AICARand+ −CompoundC,
and imaged as described previuosly [21]. In control experiments,
CRI-G1 cells took-up 2-NBDG in a linear manner for >1h .F o r
immunostaining, CRI-G1 cells were washed and immediately
ﬁxed after treatments and then permeabilized with 0.5% Triton
X-100 in PBS. Non-speciﬁc-binding was blocked with 10%
(w/v) BSA and primary antibodies against GLUT2 and GK
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Figure 2 Glucose homoeostasis in RIPCreα2KO mice
(A) Weight curves of male control and RIPCreα2KO mice on a chow diet (n=5–8). (B) Daily food intake of RIPCreα2KO and control mice (n=7–9). (C) Intraperitoneal glucose tolerance test
performed on 16-week-old male RIPCreα2KO () and control ()m i c e( n=8). (D) Insulin tolerance test performed on 20-week-old male RIPCReα2KO () and control ()m i c e( n=7). (E)
Plasmainsulinlevelsbeforeandafterintraperitonealinjectionofglucose(2g/kgofbodyweight)in10-week-oldmaleRIPCreα2KO ()andcontrol()mice(n=6–7).Valuesaremeans+ −S.E.M.
*P <0.05, **P <0.01.
(Santa Cruz Biotechnology) were applied at a 1:1000 dilution
for 1 h. For visualization, either Alexa Fluor® 488 (Molecular
Probes) or Cy3 (indocarbocyanine; Jackson ImmunoResearch)-
conjugated secondary antibodies were used according to
the manufacturers’ instructions. CRI-G1 cell nucleotide
determination was performed as described previously [9]. H2O2
levels in individual islets were measured by epiﬂuorescent
microscopy using the ﬂuorescent probe CM-H2DCFDA [5-
(and-6)-chloromethyl-2
 ,7
 -dichlorodihydroﬂuorescein diacetate,
acetyl ester] at a concentration of 1 μM, with a 60 min preloading
time.
Electrophysiological studies
Mouse cultured β-cells were super-fused at room temperature
(22–25◦C) with normal saline [135 mM NaCl, 5 mM KCl,
1m MM g C l 2, 1 mM CaCl2, 10 mM Hepes and 10 mM glucose
(pH 7.4)]. Whole-cell recordings were made using borosilicate
glass pipettes (5–10 M ) containing 140 mM KCl, 10 mM
EGTA, 5 mM MgCl2, 3.8 mM CaCl2 and 10 mM Hepes
(pH 7.2)+ −ATP at 3.0 mM, 1.0 mM, 0.1 mM and 0 mM. For
voltage-clamp recordings the membrane potential was held at
−70 mV and 20 mV steps of 200 ms duration, with 20 ms
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between pulses, applied (voltage range from −160 to −40 mV).
Voltage-clamp data were analysed using pCLAMP 8.2 software.
Perforated patch recordings were achieved by addition of 25–
50 μg/mlamphotericinB(Sigma–Aldrich)tothepipettesolution.
Series resistance was <30 M  for all recordings. Following a
minimum of 10 min of stable recording, the extracellular glucose
concentration was altered or drugs applied by bath superfusion.
Statistics
Data are presented as means+ −S.E.M. All statistics were per-
formed using GraphPad (Prism 5) software. Paired or Wilcoxon
signed-rank sum test and unpaired t tests were performed.
P values 0.05 were considered statistically signiﬁcant.
RESULTS
Deletion of AMPKα2 in the pancreas and a subset of hypothalamic
neurons does not affect body weight or food intake, but impairs
glucose homoeostasis and GSIS in mice
Mice expressing Cre under the control of the rat insulin II
promoter and mice with a ﬂoxed allele of AMPKα2 were
crossed to generate mice lacking AMPKα2 in pancreatic
β-cells and a small population [15] of hypothalamic neurons
(RIPCreα2KO mice). We detected recombination of the
ﬂoxed AMPKα2 allele in islets and hypothalamus from
RIPCreα2KO mice and protein expression of AMPKα2
was signiﬁcantly reduced in islets (Figures 1A and 1B).
No signiﬁcant change in NPY or POMC mRNA was
detected in fasted RIPCreα2KO mice (Supplementary Figure
S1A at http://www.BiochemJ.org/bj/429/bj4290323add.htm).
Furthermore, RIPCreα2KO mice exhibited normal body weight
and unchanged daily food intake compared with littermate
controls (Figures 2A and 2B), suggesting no signiﬁcant
hypothalamic phenotype. RIPCreα2KO mice displayed normal
fasted and fed blood glucose levels, and fasted plasma insulin
as compared with control mice (Supplementary Figures S1B–
S1D). RIPCreα2KO mice displayed mild glucose intolerance
compared with littermate controls (Figure 2C), but no reduction
in peripheral insulin sensitivity (Figure 2D). However, in
vivo GSIS was depressed in RIPCreα2KO mice (Figure 2E),
potentially explaining their mild glucose intolerance. To address
the possibility of compensatory up-regulation of AMPKα1
expression in cells deleted for AMPKα2, we used mice with
global deletion of AMPKα1 (α1KO), which exhibit a normal
metabolic phenotype [22] and α1KORIPCreα2KO mice (lacking
AMPKα2 in pancreatic β-cells and some hypothalamic neurons
and AMPKα1i na l lt i s s u e s ) .T h eα1KORIPCreα2KO mice
exhibited normal body weight (results not shown) and food
intake compared with controls (Figure 3A), again indicating
no hypothalamic disturbance. However, the α1KORIPCreα2KO
mice displayed profound impairment of glucose tolerance and in
vivo GSIS was markedly depressed in α1KORIPCreα2KO mice
compared with controls (Figures 3B and 3C).
AMPK-deleted islets in vitro exhibit increased insulin release at
basal glucose and decreased GSIS
Because AMPKα2 was also deleted in some hypothalamic
neurons, we were concerned that altered autonomic activity to
peripheral organs, as described for the global AMPKα2KO mouse
[22], was inﬂuencing β-cell function. We therefore undertook
further in vitro analysis of β-cell function using RIPCreα2KO
and α1KORIPCreα2KO isolated islets. Static incubation of
RIPCreα2KO islets showed enhanced insulin secretion under
Figure 3 Mice lacking AMPKα1 globally and AMPKα2i nβ-cells and
a population of hypothalamic neurons exhibit glucose intolerance and
defective GSIS
(A)Cumulative24-hfoodintakein20-week-oldmalecontrol(openbars)andα1KORIPCreα2KO
(solid bars) mice in response to an overnight fast (n=5). (B) Intraperitoneal glucose tolerance
test performed on 5-week-old male α1KORIPCreα2KO () and control ()m i c e( n=8–11).
(C) Plasma insulin levels before and after intraperitoneal injection of glucose (2g/kg of body
weight) in 10-week-old male α1KORIPCreα2KO () and control ()m i c e( n=6–7). Values
are means+ −S.E.M. **P <0.01, ***P <0.001.
basal (2 mM) glucose conditions compared with control islets,
whereas GSIS (glucose raised to 20 mM) displayed a non-
signiﬁcant trend towards decreased secretion (Figure 4A).
Furthermore, insulin secretion from α1KORIPCreα2KO islets at
2 mM glucose was enhanced and GSIS signiﬁcantly impaired
compared with control animals (Figure 4B). The increased basal
insulin secretion is consistent with that reported previously with
adenoviraloverexpressionofadominant-negativeformofAMPK
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Figure 4 Defective GSIS in isolated islets from mice lacking AMPK catalytic α subunits
(A) Insulin secretion from isolated control (open bars) and RIPCreα2KO (solid bars) islets in static cultures in response to 2 and 20mM glucose. (B) Insulin secretion from isolated control (open
bars) and α1KORIPCreα2KO (solid bars) islets in static cultures in response to 2 and 20mM glucose. (C) Pancreatic sections from control and α1KORIPCreα2KO islets, from 10-week-old male
mice, co-stained for insulin (red), glucagon (green) and DAPI (4 ,6-diamidino-2-phenylindole; blue). (D) Mean β-cell mass in islets of control and α1KORIPCreα2KO mice (n=4). Values are
means+ −S.E.M. *P <0.05, ***P <0.001.
in β-cells [10]. Taken together, these ﬁndings indicate that
appropriateexpressionofAMPKαsubunitsisrequiredfornormal
glucose sensing and GSIS in pancreatic β-cells.
Deletion of AMPKα2 does not alter β-cell mass
Recent studies show that loss of LKB1, an AMPK kinase,
increases β-cell size and enhances insulin secretion [23,24].
Therefore we undertook islet morphometric analysis in
RIPCreα2KO and control mice to exclude increased β-cell
mass as a contributing factor. Absolute β-cell mass was
unaltered in RIPCreα2KO mice compared with control animals
(Figures 4C and 4D), which indicated that altered β-cell function
underlies the changes observed in basal insulin secretion and
GSIS.
AMPKα2 is required for low-glucose-induced hyperpolarization of
pancreatic β-cells
We next examined whether the high basal insulin secretion was
associatedwithalteredβ-cellelectricalresponsivenesstoglucose.
Perforated patch recordings from single cultured isolated β-cells
showed that control (WT and RIPCre) β-cells responded
to low glucose (10 mM to 2 mM) by membrane potential
hyperpolarization causing cessation of action potential ﬁring,
actions reversed on returning to 10 mM glucose (Figures 5A
and 5B). In contrast, the majority (19 out of 24) of β-cells
from RIPCreα2KO islets displayed no hyperpolarizing response
to low glucose, maintaining an unchanged membrane potential
in 2 mM and 10 mM glucose (Figure 5C). The remaining ﬁve
cells responded normally to hypoglycaemia (results not shown),
consistent with lack of deletion of the ﬂoxed allele in all β-cells
[15].
Onepotentialissuewiththistypeofgeneticmanipulationisthat
developmentalcompensationforlossofthetargetgenemayoccur
andmodifytheobservedphenotype.Inanattempttoprecludethis
possibility,wetreatedWTmouseculturedβ-cellswithadenovirus
containing GFP (green ﬂuorescent protein) as a control or a
kinase-dead mutant form of AMPKα2, which acts as a dominant-
negative towards native AMPK (DNAMPKα2). Control viral
infectedβ-cellswereelectricallyactiveandresponded,reversibly,
to low glucose by hyperpolarization and inhibition of action
potential ﬁring (Figure 6A), identical with control β-cells. Cells
treatedwithDNAMPKα2adenoviruswerealsoelectricallyactive
in10 mMglucoseand,onreductionto2 mMglucose,asigniﬁcant
proportion of the infected cells (n=11/33) displayed no response
to hypoglycaemic challenge (Figure 6B), with the remainder
behaving as controls. The low proportion of β-cells unresponsive
to hypoglycaemia is probably related to infection efﬁciency, as
obvious GFP expression was observed in <50% of β-cells.
AttemptstoincreasetheMOI(multiplicityofinfection)toachieve
higher expression of DNAMPKα2 resulted in cell toxicity.
The non-responsive RIPCreα2KO and DNAMPKα2 β-cells
were demonstrated to be capable of hyperpolarization by their
responsiveness to the KATP activator, diazoxide, as compared with
control β-cells (Figure 6C).
Isolated islets from α1KORIPCreα2KO mice also displayed
signiﬁcantly higher insulin secretion at 2 mM glucose in
comparison with control mice. Thus to conﬁrm the role of
AMPKα2i nr e g u l a t i n gβ-cell sensitivity to hypoglycaemia, we
made recordings from β-cells of α1KO and α1KORIPCreα2KO
mice. All α1KO β-cells displayed normal responses to
hypoglycaemic challenge, with rapid hyperpolarization and
cessation of ﬁring, actions reversed on re-addition of 10 mM
glucose (Figure 6D). In contrast, the majority (7 out of 11) of
α1KORIPCreα2KO β-cells displayed little or no sensitivity to
hypoglycaemic challenge (Figure 6E), with the remaining cells
responding like controls (results not shown), as described for
RIPCreα2KO β-cells. Taken together, these ﬁndings suggest that
AMPKα2 contributes to the normal glucose sensing behaviour of
pancreatic β-cells.
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Figure 5 Loss of hypoglycaemic sensing in isolated β-cells from
RIPCreα2KO mice
WT (A)a n dRIPCre (B) mouse cultured β-cells respond, reversibly, to the reduction of glucose
from 10 to 2 mM by hyperpolarization and cessation of ﬁring. (C) RIPCreα2KO β-cells are
unresponsivetoareductionofglucoseconcentrationfrom10to2mM.Thehistogramsin(A–C)
arethemeanvaluesformembranepotentialinβ-cells exposedto10,2 and10mMglucosefor
each condition. Values were derived from seven to 19 individual β-cell recordings per group
and are shown as means+ −S.E.M. **P <0.01, ***P <0.001.
Altered AMPK levels or activity do not modify ATP levels, glucose
uptake or GK activity
Changing AMPK activity may regulate the expression,
localization or activity of GK and GLUT2 [25–28]. Therefore we
exploredwhetheralteredAMPKactivitymodiﬁedglucoseuptake
or metabolism in β-cells, using RIPCreα2KO islets and a rat β-
cell line. Although AMPKα2 mRNA was signiﬁcantly reduced in
RIPCreα2KO compared with control islets, levels of GLUT2 or
GK mRNA were unchanged (Figure 7A and Supplementary Fig-
ureS2Dathttp://www.BiochemJ.org/bj/429/bj4290323add.htm).
Additionally, there was no change in the levels of mRNA for
the low-Km hexokinase isoforms (HK I–III) in RIPCreα2KO
islets compared with control islets (Supplementary Figures
S2A–S2C). The CRI-G1 cell line was used to examine the
actions of AMPK activity modiﬁcation because it demonstrated
signiﬁcant GK expression and an innate hypersensitivity to
glucose, whereby reducing glucose from 10 mM to 2 mM did
not affect cell membrane potential or ﬁring frequency, although
lower glucose (<1 mM) levels caused hyperpolarization and
inhibition of ﬁring (Supplementary Figures S3A and S3B
at http://www.BiochemJ.org/bj/429/bj4290323add.htm). CRI-G1
cells exhibited unchanged GLUT2 or GK protein expression,
GK localization (results not shown) and glucose uptake
(Supplementary Figure S3C) following stimulation or inhibition
of AMPK activity with AICAR (1 mM) or compound C
(40 μM) respectively. We next considered the possibility that
AMPKα2 acts as a negative regulator of GK activity. GK is
the primary glucose sensor of β-cells [29] and pharmacological
activation of β-cell GK with GKA50 increases insulin secretion
at 2 mM glucose [30], mimicking the RIPCreα2KO β-cell
phenotype. Indeed, exposure of WT β-cells to 100 nM GKA50
prevented hyperpolarization and inhibition of electrical activity
by hypoglycaemic challenge (Figure 7B). Furthermore, CRI-G1
cellsdisplayedaglucoseconcentration-dependentincreaseinGK
activity (Figure 7C), signiﬁcantly higher than for INS-1 cells
(CRI-G1 cells, ∼90–100 milli-units/mg of protein; INS-1
cells, 8–10 milli-units/mg of protein at 100 mM glucose [31]).
ThisisconsistentwithCRI-G1insensitivitytolowglucoseashigh
GK activity should raise cellular ATP and maintain KATP in the
closedstate,analogoustoactivatingGKmutations,whicharealso
characterized by hypersecretion of insulin at basal glucose levels
[32]. Our initial studies appeared to corroborate this hypothesis,
as AICAR (1 mM) caused signiﬁcant inhibition (∼30%)o f
GK activity in CRI-G1 cells, at glucose concentrations above
0.5 mM, and compound C prevented this effect (Figures 7C
and 7D). Although an attractive explanation for modiﬁcation of
glucose sensing by AMPK, the inhibition of GK activity was
not replicated when AMPK activity was stimulated with the
direct AMPK activator [33], A-769662 (Figure 7E). Additionally,
the [ATP]/[ADP] ratio of CRI-G1 cells following stimulation or
inhibition of AMPK was unaffected (Figure 7F).
RIPCreα2KO islets also displayed unaltered mitochondrial
mass reﬂected by unchanged levels of ATP synthase (Figure 7G)
and mRNA levels of transcription factors involved in
mitochondrial energy metabolism, PGC1α, Tfam and Nrf were
unaltered (Figure 7A). In contrast, the mRNA level for the KATP
channel subunit, SUR1 (Figure 7A) was reduced, raising the
possibility that altered KATP current levels or ATP sensitivity
may underlie the lack of responsiveness to hypoglycaemia by
AMPKα2 deletion. However, the maximal KATP current and
ATP-sensitivity (Figures 8A and 8B) were unaltered between
RIPCreα2KO and RIPCre control β-cells. Overall, we could not
identify any alteration to glucose uptake, coupling of glucose
metabolism to mitochondrial ATP production or deﬁciency in
KATP channel function, which would explain the hypersecretion
of insulin at low glucose or the reduction in GSIS in AMPKα2-
deﬁcient β-cells.
Islets lacking AMPKα2 have reduced UCP2, and UCP2 inhibition
causes glucose insensitivity of β-cells
IncreasedUCP2activityhasbeenreportedtoimpairGSISinislets
[34,35]. Conversely, UCP2 reduction increases GSIS [36,37],
and pharmacological inhibition of UCP2 with genipin stimulates
insulin secretion [38]. UCP2 mRNA was markedly suppressed
in RIPCreα2KO islets (Figure 7A). Furthermore, exposure of
WT β-cells to genipin prevented the hyperpolarization associated
with hypoglycaemic challenge (Figure 8C), but did not inﬂuence
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Figure 6 Loss of hypoglycaemic sensing in isolated β-cells lacking AMPK activity
(A) WT mouse cultured β-cells treated with GFP adenovirus display a normal reversible response to reduction of glucose from 10 to 2 mM. (B) WT mouse cultured β-cells treated with DNAMPKα2
adenovirus exhibit loss of electrical responsiveness to hypoglycaemia. The histograms are the mean values for the change in membrane potential associated with reduction in glucose from 10 to
2 mM in responding (R, n=22) and non-responding (NR, n=11) β-cells, in comparison with control (WT) β-cells (Cont, n=7). (C) Mean change in membrane potential of control (n=12),
RIPCreα2KO (KO, n=11) and glucose-unresponsive DNAMPKα2-treated (DN, n=11) β-cells in response to application of diazoxide (250μM). (D) α1KO mouse β-cells respond normally to
reduction of glucose from 10 to 2 mM, showing typical hyperpolarization and inhibition of action potential activity. (E) α1KORIPCreα2KO β-cells are unresponsive, electrically, to hypoglycaemic
challenge. Values are means+ −S.E.M. ***P <0.001. DZX, diazoxide.
the response of the cells to diazoxide ( V control =− 19.6+ −
1.3 mV; n=5;  V genipin −19.0+ −3.7 mV; n=6). Although
genipin has been reported to have a variety of activities, at the
concentration used in the present study it is considered to act
relatively speciﬁcally [38]. In addition, genipin excites mouse
arcuate POMC neurons by closure of KATP channels only when
UCP2 is present in the neurons [39]. Consistent with our β-cell
data, hyperpolarization of POMC neurons in response to
reduced glucose is also ablated in AMPKα2KO POMC
neurons [17] and is reversibly occluded by genipin in
WT mouse POMC neurons (Supplementary Figure S4 at
http://www.BiochemJ.org/bj/429/bj4290323add.htm). However,
UCP2 reduction itself, would be predicted to increase GSIS,
whereas the loss of AMPKα2i nβ-cells resulted in diminished
GSIS. Thus we sought an alternative explanation. UCP2 activity
plays a key role in the control of mitochondrial-driven ROS
(reactive oxygen species) production [40] and a lack or reduction
of UCP2 in β-cells increases ROS and impairs GSIS from islets
[41]. However, we detected no increase in H2O2 production in
WT, RIPCreα2KO or α1KORIPCreα2KO islets at 2 or 20 mM
glucose, by CM-H2DCFDA-derived ﬂuorescence (Figure 8D).
Furthermore, we did not detect any increase in mRNA level for
antioxidantenzymesinRIPCreα2KOislets(Figure8E),indicative
ofanincreasedinnateadaptiveresponsetooxidativestress,which
has also been reported to impair GSIS [41].
DISCUSSION
A previous study has shown that global AMPKα2KO mice
demonstrate impaired glucose homoeostasis, which was ascribed
to increased catecholamine secretion [22]. In contrast, we show
that RIPCreα2KO and α1KORIPCreα2KO mice exhibit impaired
glucose tolerance associated with dysfunctional GSIS in vivo and
in isolated islets. Electrophysiological examination of AMPKα2-
depleted isolated β-cells showed that the normal inhibitory
electrical response to low glucose was ablated in the majority
of these cells compared with control β-cells, in accordance with
the observed enhanced basal insulin secretion. This outcome
indicates that the KATP channels of AMPKα2-depleted β-cells, in
contrastwithcontrolβ-cells,remainclosedunderhypoglycaemic
conditions. Elevated electrical activity and increased insulin
release at low-glucose concentrations have been reported for
β-cells with reduced levels of functional KATP channels in the
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Figure 7 AMPK activity does not correlate with altered GK activity, nucleotide ratios or mitochondrial mass
(A)Relative islet mRNAexpression,from20-week-oldmalecontrolandRIPCreα2KO mice,ofAMPKα2,Gck,Slc2a2,Nrf1,PGC1a,SUR1,Tfam andUCP2 (n=6).(B)WT mouseculturedβ-cells
treated with 100nM GKA50 fail to respond electrically to hypoglycaemic challenge, but respond normally to diazoxide (250 μM; DZX). Histograms are the mean values for membrane potential in
β-cells exposed to 10mM glucose alone, and 10, 2 and 10mM glucose in the presence of GKA. (C) Activity of GK in CRI-G1 β-cells as a function of glucose concentration in the absence ()a n d
presence()ofAICAR(1 mM).Thecurvedlines(Control,solid;AICAR,broken)representlinesofbestﬁttothedatapoints(n=5–8determinationsperpoint).(D)GKactivity,expressedrelativeto
control conditions (6mM glucose), in CRI-G1 β-cells exposed to 1mM AICAR + −40μM Compound C in 6mM glucose (n=5–8 determinations for each condition). (E) Activity of GK in CRI-G1
β-cells as a function of glucose concentration in the absence () and presence () of A-769662 (10μM). The curved lines (Control, solid; A-769662, broken) represent lines of best ﬁt to the
data points (n=6 determinations per point). (F) Mean values for the [ATP]/[ADP] ratio of CRI-G1 β-cells in control conditions and treated with 10μM A-769662+ −40μM Compound C (n=3–6
determinations for each condition). (G) Representative immunoblot for ATP synthase from control and RIPCre2αKO islets. A-76, A-769662; cont, control; Cpdc, compound C.
plasma membrane [42,43], or which have loss of function
mutations in one of the KATP channel subunits, KIR6.2 or
SUR1 [44]. It has also been suggested that AMPK can modify
β-cell KATP activity by phosphorylation of KIR6.2 [45] or altered
plasma membrane channel numbers [46]. However, this is
unlikely to explain AMPKα2KO β-cell electrical insensitivity to
hypoglycaemia because the cells display normal hyperpolarizing
responses to diazoxide and exhibit an unaltered maximal KATP
current compared with control cells. An alternative explanation is
thatlackofAMPKα2activitydecreasesKATP currentbyincreased
channel ATP sensitivity causing maintained KATP closure in
the face of reduced cell ATP levels during the hypoglycaemic
challenge. However, we could detect no difference in the ATP-
sensitivity of KATP comparing AMPKα2-null and control β-cells.
Reduced expression of GLUT2 in rodents and humans
correlateswithβ-cellglucoseinsensitivity[8,47].However,aswe
could detect no evidence to link altered AMPK levels or activity
to a change in GLUT2 mRNA or protein levels or to glucose
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Figure 8 Loss of AMPKα2 does not alter β-cell KATP current or ATP-sensitivity or islet ROS response
(A)Representativecurrent–voltagerelationshipsforvoltage-clampedcurrentsofRIPCre control(blacksymbols)andaRIPCreα2KO (greysymbols)culturedβ-cells.Meancurrentsweremeasuredat
variousmembranepotentialsshortlyafterattainingwhole-cellrecording(i.e.priortosigniﬁcantwashoutofcellATP;ﬁlledsquares)and20minlater(followingmaximalwashoutofcellularATP;ﬁlled
circles). (B) Mean slope conductance values for current–voltage relationships as shown in (A), as a function of [ATP] (0, 0.5, 1.0 or 3.0mM in the pipette solution). Lines of best ﬁt (dose–response)
are shown for RIPCre control (black ﬁlled squares) and RIPCreα2KO (grey ﬁlled circles) β-cells (n=3–6). (C)W Tβ-cells exposed to genipin (100nM) are electrically unresponsive to the
reduction of glucose from 10mM to 2mM. Note that 250μM diazoxide (DZX) hyperpolarizes the cell in the presence of genipin. Histograms are the mean values for membrane potential for
β-cells, in the presence of genipin exposed to 10, 2 and 10mM glucose respectively (n=6). (D)H 2O2-derived ﬂuorescence in isolated islets of control, RIPCreα2KO and α1KORIPCreα2KO mice
(n=16–23islets each) at 2 and 20 mM glucose. A. U., arbitray units. (E) Expression of antioxidant enzymes in isolated islets of RIPCreα2KO mice, normalized to the levels expressed in control
WT mice (n=8–10). *P <0.05.
uptake, this component of β-cell glucose sensing is unlikely to be
responsibleforthedefectivecontrolofinsulinsecretiondescribed
in the present study. Deletion of the upstream AMPK regulator
LKB1 results in improved glucose tolerance, β-cell hypertrophy,
higher insulin content and increased secretion in vivo and in
vitro [23,24]. These results have been interpreted as LKB1, by
increasing AMPK activity, acting to restrain insulin secretion.
However, we observe no change in β-cell mass, and GSIS
in AMPKα2-deleted islets is impaired not enhanced, indicating
that AMPKα2 β-cell deletion is unlikely to be associated with
reduced LKB1 activity. Our results also indicate that the outcome
of LKB1 deletion in β-cells described in these reports may not be
due simply to altered AMPK activity.
GK plays a central role in the control of GSIS because it allows
glucose phosphorylation at physiological glucose concentrations.
Inactivating mutations of GK result in reduced insulin secretion
and Type 2 diabetes, whereas GK-activating mutations cause
insulin hypersecretion and hypoglycaemia [48]. Thus high GK
activity should result in high levels of ATP at low-glucose
concentrationsandkeepKATP channelsclosed.Indeed,stimulation
of GK with GKA50 in control β-cells resulted in the loss of
electricalsensitivitytolowglucose.Insupportofthisnotion,CRI-
G1 cells have reduced sensitivity to hypoglycaemic challenge
and express high GK activity. Furthermore, stimulation of AMPK
activitywithAICARsigniﬁcantlyreducedGKactivity,whichwas
prevented by co-application of the AMPK inhibitor compound C.
Although these results encouraged the view that loss of AMPKα2
up-regulated GK activity in β-cells, this effect was not replicated
using the direct AMPK activator A-769662. In addition, we
could detect no change in the levels of low-Km hexokinases in
AMPKα2-deleted islets, abrogating an induction of one or more
of these hexokinases as a potential loss-of-function mediator.
Taken together with the lack of change in bulk [ATP]/[ADP]
ratio in CRI-G1 cells, we think it unlikely that modiﬁcation of
GK activity explains the insensitivity of β-cell electrical activity
to low glucose in AMPKα2-deﬁcient cells.
β-cells have a relatively modest endogenous antioxidant
defence system and are very susceptible to toxicity induced
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by ROS [49]. Increased respiratory energy production raises
mitochondrial electron transport, which drives the generation of
ROS. To counter this, pancreatic β-cells exhibit high UCP2 levels
and activity, which uncouples respiratory energy production,
reduces the mitochondrial membrane potential and attenuates
ROS production [37]. UCP2 may be a crucial component
of β-cell function as inappropriately high UCP2 levels (e.g.
associated with chronic hyperglycaemia or obesity) or UCP2
overexpression causes β-cell dysfunction by lowering ATP levels
and reducing GSIS [36]. Conversely, knockdown of UCP2 in
isletsorglobalUCP2-deﬁcientmiceexhibitraisedisletATPlevels
and increased insulin secretion [34]. Our ﬁnding that AMPKα2
deletionreducesUCP2mRNAlevelsinisletsmightthereforehave
led to the prediction that insulin secretion would be increased.
Clearly, this was not the case when GSIS was examined in
vivo or in vitro in RIPCreα2KO and α1KORIPCreα2KO mice.
Indeed, in isolated islets although basal insulin secretion in
the presence of low glucose was enhanced, GSIS was either
relativelyunaffected(RIPCreα2KOmice)orsigniﬁcantlyreduced
(α1KORIPCreα2KO mice) compared with controls.
The ﬁnding that AMPKα2 deletion also ablates the KATP-
mediated hyperpolarization associated with hypoglycaemia in
hypothalamic POMC neurons [17] supports the notion that
AMPKα2 deletion alters β-cell glucose sensing capability.
Furthermore, KATP activation by low glucose is occluded in both
cell types by genipin, supporting the idea that UCP2 activity is
a key component of hypoglycaemic sensing in these specialized
cells. So how might we explain the reduced GSIS associated
with loss of AMPKα2 and reduced UCP2 in β-cells? There is a
growing body of evidence to indicate that β-cell ROS production
contributes to glucose-sensing behaviour and the regulation of
insulin secretion, either as a signal for insulin secretion or as
a mediator of the adaptive antioxidant response [41]. However,
t h er e d u c t i o no fU C P 2i nA M P K α2-deleted islets was not
accompaniedbyanysigniﬁcantalterationinROSlevelsatlow-or
high-glucose concentrations, and we could detect no evidence for
anadaptiveresponsecausingraisedlevelsofantioxidantenzymes.
The permanently depolarized nature of AMPKα2-null β-cells
may be, at least partly, responsible for the overall reduction of
GSISandimpairedglucosetoleranceweobserveinRIPCreα2KO
mice. This notion arises from reports that suppression of insulin
secretion by pharmacological opening of KATP channels causing
cellhyperpolarizationandaperiodofrestfortheinsulinsecretion
process improves glucose tolerance and β-cell function in animal
models of diabetes and preserves and improves human islet
function [50]. Thus maintenance of AMPK activity may be
an important component of β-cell protection against chronic
overstimulation and loss of islet function.
In conclusion, loss of AMPKα2 appears to cause permanently
dampened UCP2 levels in islets, which is associated with
dysfunctional β-cell glucose sensing and diminished GSIS. Lack
of AMPKα2 may therefore result in disconnection of the normal
response to nutrient deprivation whereby raised AMPK activity
and UCP2 levels would act to lower insulin secretion at low-
glucoselevelsandmaintainsecretionathigh-glucoselevels.Thus
wehypothesizethatAMPKplaysakeyroleinconnectingnutrient
ﬂuctuations and UCP2 regulation with maintenance of GSIS in
β-cells.
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Figure S1 Hypothalamic mRNA expression proﬁle and glucose homoeostasis parameters in RIPCreα2KO mice
(A) Expression of mRNA in the hypothalamus of RIPCreα2KO mice, relative to control WT mice (n=5). Fasting (B)a n df e d( C) blood glucose levels in control (n=8) and RIPCreα2KO 16- and
20-week-old male mice respectively (n=8). (D) Fasted plasma insulin levels in control (n=9) and RIPCreα2KO 10-week-old male mice (n=7).
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Figure S2 Expression of mRNA in islets of RIPCreα2KO mice, relative to control (RIPCre) islets for (A) HK I, (B) HK II, (C) HK III, and (D) GK
Values are means+ −S.E.M. for n=7–9 determinations for each. The probes used were: Hexokinase I, Mm01145241_m1; Hexokinase II, Mm00443395_m1; and Hexokinase III, Mm01341937_m1.
Figure S3 CRI-G1 β-cells exhibit glucose-sensing behaviour, and AMPK
manipulation does not inﬂuence glucose uptake
Representative perforated patch recordings from CRI-G1 β-cells, showing (A) the lack of
electrical response to reduction of glucose from 10 mmol/l to 2 mmol/l and (B)t h e
hyperpolarization and inhibition of ﬁring on reduction of glucose from 10 mmol/l to 0.1
mmol/l.Notethattheapplicationof250μmol/ldiazoxide(DZX)hyperpolarizestheβ-cellinthe
presenceof10mmol/lglucose.(C)Glucoseuptake,asmeasuredby2-NBDGuptake,inCRI-G1
β-cells is unaltered by treatment of cells (1 h) with 1 mmol/l AICAR + −40 μmol/l compound C
(CpdC) (n=44, from six separate experiments).
FigureS4 RepresentativeperforatedpatchrecordingfromaPOMCarcuate
nucleus neuron
Reducingglucosefrom2mMto0.1mMreversiblyhyperpolarizesandreducesﬁringfrequency,
but this effect is reversibly occluded by the presence of 20 μM genipin. The broken line in the
trace represents 0 mV.
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